Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017 (2017), Article ID 7072615, 4 pages
https://doi.org/10.1155/2017/7072615
Case Report

All That Wheezes Is Not Asthma: A Case of Diffuse Large B-Cell Lymphoma of the Larynx

1University of Arizona College of Medicine, Tucson, AZ, USA
2Department of Medicine, University of Arizona, Tucson, AZ, USA
3Department of Hematology & Oncology, University of Arizona, Tucson, AZ, USA

Correspondence should be addressed to Bushra Rahman; ude.anozira.liame@namharb

Received 5 November 2016; Revised 1 March 2017; Accepted 2 March 2017; Published 15 March 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Bushra Rahman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. A. Anderson, R. H. Maisel, and R. W. Cantrell, “Isolated laryngeal lymphoma,” Laryngoscope, vol. 86, no. 8, pp. 1251–1257, 1976. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Franzen and M. O. Kurrer, “Malignant lymphoma of the larynx: case report and review of the literature,” Laryngo-Rhino-Otologie, vol. 79, no. 10, pp. 579–583, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Ansell, T. M. Habermann, J. D. Hoyer, J. G. Strickler, M. G. Chen, and T. J. McDonald, “Primary laryngeal lymphoma,” Laryngoscope, vol. 107, no. 11, part 1, pp. 1502–1506, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Cavalot, G. Preti, N. Vione, G. Nazionale, F. Palonta, and G. L. Fadda, “Isolated primary non-Hodgkin's malignant lymphoma of the larynx,” Journal of Laryngology and Otology, vol. 115, no. 4, pp. 324–326, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. H.-P. Horny and E. Kaiserling, “Involvement of the larynx by hemopoietic neoplasms—an investigation of autopsy cases and review of the literature,” Pathology Research and Practice, vol. 191, no. 2, pp. 130–138, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. B. D. Cheson, R. I. Fisher, S. F. Barrington et al., “Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification,” Journal of Clinical Oncology, vol. 32, no. 27, pp. 3059–3067, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. F. Barrington, N. G. Mikhaeel, L. Kostakoglu et al., “Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group,” Journal of Clinical Oncology, vol. 32, no. 27, pp. 3048–3058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, “A predictive model for aggressive non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993. View at Publisher · View at Google Scholar
  9. L. H. Sehn, B. Berry, M. Chhanabhai et al., “The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP,” Blood, vol. 109, no. 5, pp. 1857–1861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Coiffier, C. Thieblemont, E. Van Den Neste et al., “Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A Study by the Groupe d'Etudes des Lymphomes de l'Adulte,” Blood, vol. 116, no. 12, pp. 2040–2045, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. H. Sehn, “Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma,” Hematology. American Society of Hematology. Education Program, vol. 2012, no. 1, pp. 402–409, 2012. View at Google Scholar
  13. G. Lenz, G. Wright, S. Dave et al., “Stromal gene signatures in large-B-cell lymphomas,” New England Journal of Medicine, vol. 359, no. 22, pp. 2313–2323, 2008. View at Publisher · View at Google Scholar
  14. G. S. Nowakowski and M. S. Czuczman, “ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?” American Society of Clinical Oncology, pp. e449–e457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. K. Ng, B. S. Dabaja, R. T. Hoppe, T. Illidge, and J. Yahalom, “Re-examining the role of radiation therapy for diffuse large B-cell lymphoma in the modern era,” Journal of Clinical Oncology, vol. 34, no. 13, pp. 1443–1447, 2016. View at Publisher · View at Google Scholar
  16. G. Held, N. Murawski, M. Ziepert et al., “Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma,” Journal of Clinical Oncology, vol. 32, no. 11, pp. 1112–1118, 2014, Proceedings of the Annual Meeting of the American Society of Hematology, San Francisco, Calif, USA, December 2008, and 17th Annual Meeting of the European Hematology Association, Amsterdam, The Netherlands, June 2012. View at Publisher · View at Google Scholar
  17. T. P. Miller, S. Dahlberg, J. R. Cassady et al., “Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 339, no. 1, pp. 21–26, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Reyes, E. Lepage, G. Ganem et al., “ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma,” The New England Journal of Medicine, vol. 352, no. 12, pp. 1197–1205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Rowley, R. D. McRae, J. A. Cook, T. R. Helliwell, D. Husband, and A. S. Jones, “Lymphoma presenting to a head and neck clinic,” Clinical Otolaryngology & Allied Sciences, vol. 20, no. 2, pp. 139–144, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Rowley, R. D. McRae, J. A. Cook, T. R. Helliwell, D. Husband, and A. S. Jones, “Lymphoma presenting to a Head and Neck Clinic,” Clinical Otolaryngology & Allied Sciences, vol. 20, no. 2, pp. 139–144, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-H. Chien, C.-J. Liu, Y.-W. Hu et al., “Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study,” International Journal of Cancer, vol. 137, no. 3, pp. 658–665, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Tilly, M. Gomes da Silva, U. Vitolo et al., “Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 26, pp. v116–v125, 2015. View at Publisher · View at Google Scholar · View at Scopus